Translation

Translation is the final step of the central dogma (DNA to RNA to Protein). It occurs on ribosomes, which consist of a large and small subunit. The mRNA sequence is read in groups of three nucleotides called codons. Each codon specifies a particular amino acid. Transfer RNA (tRNA) acts as the bridge; it has an anticodon that matches the mRNA codon and carries the corresponding amino acid. The process has three stages: Initiation (assembly of the ribosome around the start codon AUG), Elongation (sequential addition of amino acids via peptide bonds), and Termination (triggered by a stop codon). In eukaryotes, translation often occurs on the Rough Endoplasmic Reticulum (RER) for proteins destined for secretion or membrane insertion. Post-translational modifications, such as phosphorylation, glycosylation, or proteolytic cleavage (e.g., pro-insulin to insulin), are often required to activate the protein. Many antibiotics target bacterial translation, exploiting the structural differences between prokaryotic (70S) and eukaryotic (80S) ribosomes.

Initiation begins when the small ribosomal subunit binds the 5' cap of mRNA and scans for the AUG start codon. A specialized initiator tRNA (carrying methionine) binds at the P-site. Elongation involves three sites on the ribosome: A (aminoacyl), P (peptidyl), and E (exit). A new tRNA enters the A-site, a peptide bond is formed between its amino acid and the growing chain in the P-site, and then the ribosome translocates, moving the empty tRNA to the E-site. This requires energy from GTP. Termination occurs when a release factor binds to a stop codon in the A-site, causing the polypeptide to be released. After synthesis, proteins undergo folding, often assisted by 'chaperone' proteins. Prion diseases (like CJD) occur when this folding goes wrong. Post-translational modifications further refine protein function; for instance, gamma-carboxylation of clotting factors (using Vitamin K) is essential for their ability to bind calcium and participate in coagulation.

Many antibiotics target the 70S ribosome: Macrolides (e.g., Erythromycin) and Clindamycin inhibit the 50S subunit, while Aminoglycosides (e.g., Gentamicin) and Tetracyclines inhibit the 30S subunit. This selective toxicity is the basis of antibacterial therapy. Shiga toxin (from E. coli) and Ricin act by inactivating the 60S ribosomal subunit, halting protein synthesis and causing cell death. Insulin production is a classic example of post-translational processing, where C-peptide is cleaved; measuring C-peptide is clinically useful to distinguish endogenous insulin production from injected insulin. I-cell disease is a rare disorder of post-translational modification (lysosomal enzyme targeting).

Clinical investigations related to protein synthesis include: Serum protein electrophoresis (to look for monoclonal gammopathies like Myeloma), C-peptide levels (for insulin evaluation), and specific assays for clotting factor activity (checking for gamma-carboxylation status in Vitamin K deficiency or Warfarin use).

Management of translation-related issues includes using specific antibiotics for bacterial infections. For diseases of protein misfolding like Amyloidosis, management focuses on organ support (e.g., renal or cardiac) and chemotherapy to stop the production of the precursor proteins. Vitamin K supplementation is used to ensure proper post-translational carboxylation of clotting factors in neonates or patients with bleeding risks.